Computer-implemented means and methods for the novo design of antibodies targeting a specific epitope

Antibody-based therapeutics have emerged as pivotal therapeutic agents to combat various diseases, drastically expanding the therapeutic options available to patients and clinicians. Over the last decade, the vast majority of biologic license applications approved by the FDA are therapeutic antibodies. Traditional methodologies for antibody discovery, rooted in animal immunizations, hybridoma technologies, and phage display, have been crucially important to establish the potential and positioning of antibody-based therapeutics. However, these approaches are fraught with fundamental challenges such as suboptimal developability, limited and unpredictable cross-reactivity of the developed antibodies, and difficulties in targeting conserved binding epitopes. These limitations necessitate a paradign shift towards innovative approaches to address the evolving demands of antibody development. Classical antibody discovery processes are often time-consuming, labor-intensive and entail sequential stages that prioritize antigen-binding over other critical parameters such as manufacturability and long-term stability. This sequential approach results in significant efforts being spent in later stages to optimize these parameters independently, leading to increased costs and timelines, and sometimes adverse effects on initial affinities. Furthermore, ethical concerns regarding the use of animal models for immunization and the challenges associated with immune responses in host organisms pose additional hurdles.The present invention relates to methods and systems which relate to the biomedical field and relate to subfields of computational biology and bioinformatics. More, specifically the invention provides a computer-implemented algorithm which can produce a panel of antibodies directed to an epitope of choice.